As gene therapies advance toward indications with larger patient populations, adeno-associated virus (AAV) manufacturers are under growing pressure to deliver high-quality vectors at substantially larger scales. One of the most persistent upstream challenges in AAV production is the need to add large volumes of transfection complex to bioreactors within a narrow and unforgiving time window. At the manufacturing scale, this constraint increases operational complexity, labor requirements, and overall process risk.
The VirusGEN® Transfection Complex Stabilizer was developed to address this bottleneck in large-scale AAV manufacturing. When used with TransIT-VirusGEN® Transfection Reagent, the stabilizer reduces the required transfection complex volume from the industry standard of approximately five percent to just two percent of the total cell culture volume. By minimizing the volume added to the bioreactor, manufacturers can reduce dilution effects and significantly lower consumption of costly media or buffer solution, delivering meaningful improvements in process economics while simplifying large-scale operations.
Experimental data further demonstrate that improvements in AAV titer and the percentage of full capsids are achieved when the stabilizer is used as part of the fully optimized VirusGEN workflow, which includes TransIT-VirusGEN Transfection Reagent and RevIT AAV Enhancer.
The time sensitivity of AAV transfection
Successful production of high-titer AAV vectors at scale is fundamentally a race against time. During AAV manufacturing, a transfection complex composed of plasmid DNA (pDNA) and a transfection reagent delivers genetic material into host cells. The transfection complex is formed by diluting pDNA in a complexation buffer, followed by the addition of a transfection reagent. After a defined incubation period, the resulting complexes are introduced into the cell culture to initiate transfection.
The size of the transfection complex during this preparation and delivery window, typically measured in minutes, has a direct impact on viral vector yield. During this time, transfection complexes can grow due to interactions among cationic polymers, cationic lipids, and DNA. As transfection complex size increases, cellular uptake efficiency decreases, leading to reduced transfection efficiency and lower AAV titers.
Significantly extending stability
Traditional AAV transfection workflows demand precise coordination to ensure complexes are delivered while still within an optimal size range. This requirement becomes particularly challenging at manufacturing scale when operating at hundreds of liters, where logistical constraints are unavoidable.
The VirusGEN Transfection Complex Stabilizer, when combined with TransIT-
VirusGEN Transfection Reagent to support the formation of transfection complexes that exhibit minimal growth, improves time management. As a result, manufacturers gain greater process flexibility without sacrificing performance, as the stabilizer extends the usable window of prepared transfection complexes from 30 minutes to up to three hours, while maintaining AAV titer and product quality.
In addition to extending complex stability, the stabilizer enables a more concentrated transfection solution, reducing the transfection complex volume required for delivery to the bioreactor from five percent to two percent of the total culture volume. This dual benefit of prolonged stability and reduced volume addresses two of the most significant constraints in upstream AAV manufacturing.
Impact on titer and capsid quality
The prolonged stability window facilitated by the VirusGEN Transfection Complex Stabilizer enables greater process flexibility, helping ensure consistent delivery of transfection complexes with reduced time pressure. This improvement is reflected in AAV productivity and quality metrics, such as viral genome titers (vg/mL) and percent full capsids.
To assess AAV9 production across common transient transfection approaches, we compared vector genome titer and the percentage of full capsids as key readouts. Across conditions, improvements in transfection complex stability over time were observed only when the VirusGEN Transfection Complex Stabilizer was used in combination with the TransIT‑VirusGEN Transfection Reagent.
Reducing the transfection complex volume to two percent of the total culture volume provides multiple benefits for the production process, including delivering a smaller volume to the bioreactor and minimizing dilution effects, which helps preserve nutrient concentrations and culture conditions.
Designed for production-scale success
The benefits of prolonged transfection complex stability can extend beyond individual runs, translating into potential improvements in reproducibility, scalability, and reduced process variability throughout a manufacturing campaign. These advantages become especially important as production scales increase from 500 L to 1,000 L bioreactors and beyond.
By expanding the allowable window for complex preparation and addition, the VirusGEN Transfection Complex Stabilizer reduces the operational burden associated with large-volume transfections. Operators can execute transfections in a controlled, predictable manner rather than under tight time constraints, improving consistency across batches and reducing the risk of variability introduced by time-sensitive execution.
Conclusion
The VirusGEN Transfection Complex Stabilizer is the first transfection additive engineered specifically to simplify upstream AAV production at manufacturing scale. Compatible exclusively with TransIT-VirusGEN Transfection Reagent, it preserves established process parameters and integrates seamlessly into existing VirusGEN-based workflows, enabling rapid adoption in GMP environments.
By reducing the volume of material added to the bioreactor and transforming a highly time-sensitive step into a stable and more predictable process, the stabilizer eliminates the need for later transfection complex stabilization steps and additional process manipulations, supporting reliable scale-up to batch sizes required for GMP production. The extended stability window allows operators to work efficiently and consistently, without the operational pressure that traditionally accompanies large-scale AAV transfection.
The ability to reliably scale AAV production is foundational to the future of gene therapy, and stabilizing upstream AAV vector production helps manufacturers move programs from clinical promise toward commercial reality. By enabling consistent, high-titer AAV production at scale, the VirusGEN Transfection Complex Stabilizer, combined with TransIT-VirusGEN and RevIT AAV Enhancer, allow manufacturers to focus on what matters most: delivering reliable, high-quality viral vectors to support today’s transformative gene therapies.
John Schiel, PhD, is senior product manager, Mirus Bio.
